Skip to content

Effectiveness of Care Management in Alzheimer Patients

Evaluation de la Mise en Place d'un Auxiliaire d'évaluation Dans la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées en France

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01081743
Acronym
AIDALZ
Enrollment
270
Registered
2010-03-05
Start date
2009-11-24
Completion date
2013-10-02
Last updated
2017-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease or Associated Disorder, Mild to Moderately Severe Dementia

Keywords

Alzheimer, Dementia, Mild to moderately severe, New diagnosis, Prevention of behavioural problems

Brief summary

Context: The French Alzheimer plan 2008-2012 includes the implementation of disease managers or social workers, from the onset of the disease, for every patient with a diagnosis of Alzheimer disease or associated disorder. However, previous trials evaluating the efficacy of a systematic intervention for each case from the onset of the disease, including non complex cases, have shown little evidence. Objective: To evaluate the efficacy of a social worker to prevent behavioural problem for patient with a new diagnosis of Alzheimer disease or associated disorder. Design and setting: Multicentric cluster randomized control trial. Patients from several memory consultations and specialists (neurologist, psychiatrist or geriatrician) in France are included. Intervention: In addition to usual care, patients in the intervention group have systematic home visits from a social worker and regular follow-ups by phone over a one-year period. This social worker informs the patient and caregiver, evaluates the needs, gives advices to prevent complications and is a link between the patient and the memory consultation or the specialist. Patient in the control group have absolutely no intervention and are followed-up as usually. In order to not modify the usual care, they have no information on their participation in this trial before the one-year evaluation. Main outcome measure: NeuroPsychiatric Inventory (NPI) administrated at one year, which evaluates frequency, severity and repercussion of several behavioural problems. Secondary outcomes included disability, cognition, depression, health, quality of life, institutionalization, and resource use.

Interventions

OTHERIntervention of the social worker

Systematic home visits and regular follow-ups by phone from a social worker

Sponsors

Institut de Sante Publique, d'Epidemiologie et de Developpement
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of Alzheimer's Disease or other dementia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition \[DSM IV\] criteria of dementia) * Presence of an informal caregiver * Mild to moderately severe dementia (MMSE \[10-28\]) * Diagnosis of dementia made by a specialist ≤ 6 months * Patient affiliated to the national health insurance system

Exclusion criteria

* Institutionalized patient * Patient on legal guardianship * Behavioural problem with important clinical repercussion * Psychotic syndrome * Severe and unstable general pathology

Design outcomes

Primary

MeasureTime frameDescription
NeuroPsychiatric Inventory (NPI)1 yearEvaluation of frequency, severity and repercussion of several behavioural problems

Secondary

MeasureTime frame
Questionnaire Quality of Life - Alzheimer's Disease (QoL-AD)1 year
Burden Interview of Zarit1 year
Resource utilization in dementia scale (RUD Lite)1 year
Medical Outcome Study Short Form 36-item health survey (MOS SF-36)1 year
Institutionalization1 year
Montgomery-Asberg Depression Rating Scale (MADRS)1 year
Cohen-Mansfield Agitation Inventory (CMAI)1 year
Apathy Inventory1 year
Disablement Assessment for Dementia (DAD)1 year
Mini Mental State Examination (MMSE)1 year
Global Deterioration Scale (GDS)1 year
Tiredness scale1 year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026